臨床検査52巻13号

2008年12月発行

今月の主題 凝固制御 トピックス

血友病患者インヒビターの産生と制御

著者： 瀧正志¹

所属機関： ¹聖マリアンナ医科大学横浜市西部病院小児科

ページ範囲：P.1593 - P.1597

1．はじめに

　血友病の止血治療は20世紀後半大きく進歩し，重篤な出血の止血管理および大手術も可能となった．しかし，21世紀に残された課題もまだ多く，その一つは根治療法である．その方略の一つとして遺伝子治療に大きな期待が寄せられているが，臨床応用までには解決すべき問題が多い．もう一つの大きな課題は，インヒビターに関連することで，インヒビター発生時の止血治療，インヒビターの消失をはかる治療法，さらにインヒビターを発生させない治療法の確立である．インヒビターに関していまだ不明な点が多く，本稿ではインヒビターの産生と制御について，最近の知見を中心に概説したい．

参考文献

1) 血液凝固異常全国調査委員会：血液凝固異常症全国調査　平成17年度報告書，エイズ予防財団，pp9，2006

2) Kasper CK, Aledort L, Aronson D, et al：Proceedings：A more uniform measurement of factor Ⅷ inhibitors. Thromb Diath Haemorrh　34：612, 1975

3) Verbruggen B, Novakova I, Wessels H, et al：The Nijmegen modification of the Bethesda assay for factor Ⅷ：C inhibitors：improved specificity and reliability. Thromb Haemost　73：247-251, 1995

4) Biggs R, Bidwell E：A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol　5：379-395, 1959

5) 山崎哲，鈴木典子，山崎法子，他：第Ⅷ因子インヒビター測定の特性および不活化処理の有用性．日本血栓止血学会誌　19：235-243，2008

6) Dazzi F, Tison T, Vianello F, et al：High incidence of anti-FⅧ antibodies against non-coagulant epitopes in haemophilia A patients：a possible role for the half-life of transfused FⅧ. Br J Haematol　93：688-693, 1996

7) Sawamoto Y, Shima M, Yamamoto M, et al：Measurement of anti-factor Ⅸ IgG subclass in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor Ⅸ concentrates. Thromb Res　83：279-286, 1996

8) Fijnvandraat K, Celie PH, Turenhout EA, et al：A human alloantibody interferes with binding of factor Ⅷ to the factor Ⅷ light chain. Blood　91：2347-2352, 1998

9) Zhong D, Saenko EL, Shima M, et al：Some human inhibitor antibodies interfere with factor Ⅷ binding to factor Ⅸ. Blood　92：136-142, 1998

10) Lollar P, Parker ET, Curtis JE, et al：Inhibition of human factor Ⅷa by anti-A2 subunit antibodies. J Clin Invest　93：2497-2504, 1994

11) Arai M, Scandella D, Hoyer LW：Molecular basis of factor Ⅷ inhibition by human antibodies. Antibodies that bind to the factor Ⅷ light chain prevent the interaction of factor Ⅷ with phospholipid. J Clin Invest　83：1978-1984, 1989

12) Shima M, Scandella D, Yoshioka A, et al：A factor Ⅷ neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor Ⅷ binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost　69：240-246, 1993

13) Saenko EL, Shima M, Gilbert GE, et al：Slowed release of thrombin-cleaved factor Ⅷ from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor Ⅷ inhibition. J Biol Chem　271：27424-27431, 1996

14) Gawryl MS, Hoyer LW：Inactivation of factor Ⅷ coagulant activity by two different types of human antibodies. Blood　60：1103-1109, 1982

15) Lacroix-Desmazes S, Moreau A, Sooryanarayana Bonnemain C, et al：Catalytic activity of antibodies against factor Ⅷ in patients with hemophilia A. Nat Med　5：1044-1047, 1999

16) Astermark J：Basic aspects of inhibitors to factor Ⅷ and Ⅸ and the influence of non-genetic risk factors. Haemophilia　6：8-13, 2006

17) Scharrer I, Bray GL, Neutzling O：Incidence of inhibitors in haemophilia A patients：a review of recent studies of recombinant and plasma-derived factor Ⅷ concentrates. Haemophilia　5：145-154, 1999

18) Gill JC：The role of genetics in inhibitor formation. Thromb Haemost　82：500-504, 1999

19) Astermark J, Oldenburg J, Pavlova A, et al：Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood　107：3167-3172, 2006

20) Reding MT, Okita DK, Diethelm-Okita BM, et al：Human CD4＋T cell epitope repertoire on the C2 domain of coagulation factor Ⅷ. J Thromb Haemost　1：1777-1784, 2003

21) Lei TC, Scott DW：Induction of tolerance to factor Ⅷ inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood　105：4865-4870, 2005

22) Rawle FE, Pratt KP, Labelle A, et al：Induction of partial immune tolerance to factor Ⅷthrough prior mucosal exposure to the factor ⅧC2 domain. J Thromb Haemost　4：2172-2179, 2006

23) Dobrzynski E, Fitzgerald JC, Cao O, et al：Prevention of cytotoxic T lymphocyte responses to factor Ⅸ-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Nat Acad Sci USA　103：4592-4597, 2006

24) Goudemand J, Rothschild C, Demiguel V, et al：Influence of the type of factor Ⅷ concentrate on the incidence of factor Ⅷ inhibitors in previously untreated patients with severe hemophilia A. Blood　107：46-51, 2006

25) Gouw SC, van der Bom JG, Auerswald G, et al：Recombinant versus plasma-derived factor Ⅷ products and the development of inhibitors in previously untreated patients with severe hemophilia A：the CANAL cohort study. Blood　109：4693-4697, 2007

26) Gouw SC, van der Bom JG, Marijke van den Berg H：Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A：the CANAL cohort study. Blood　109：4648-4654, 2007

27) Lorenzo JI, López A, Altisent C, et al：Incidence of factor Ⅷ inhibitors in severe haemophilia：the importance of patient age. Br J Haematol　113：600-603, 2001

28) Brackmann HH：Induced immunotolerance in factor Ⅷ inhibitor patients. Prog Clin Biol Res　150：181-195, 1984

29) Brackmann HH, Oldenburg J, Schwaab R：Immune tolerance for the treatment of factor Ⅷ inhibitors--twenty years' ‘bonn protocol'. Vox Sang　70：30-35, 1996

30) Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, et al：Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood　86：983-988, 1995

31) Nilsson IM, Berntorp E, Zettervall O：Induction of immune tolerance in patients with hemophilia and antibodies to factor Ⅷ by combined treatment with intravenous IgG, cyclophosphamide, and factor Ⅷ. N Engl J Med　318：947-950, 1988

32) Freiburghaus C, Berntorp E, Ekman M, et al：T Tolerance induction using the Malmötreatment model 1982-1995. Haemophilia　5：32-39, 1999

33) Mariani G, Ghirardini A, Bellocco R：Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor Ⅷ and Ⅸ Subcommittee. Thromb Haemost　72：155-158, 1994

34) DiMichele DM, Kroner BL：Analysis of the North American Immune Tolerance Registry(NAITR)1933-1997：Current practice implications. Vox Sang　77：31-32, 1999

35) Warrier I, Ewenstein BM, Koerper MA, et al：Factor Ⅸ inhibitors and anaphylaxis in hemophilia B. J Pediatr Haematol Oncol　19：23-27, 1997

36) Ewenstein BM, Takemoto C, Warrier I, et al：Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood　89：115-116, 1997